<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Primary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) occur in the absence of exposure to ionizing radiation, chemotherapeutic agents or myelotoxic drugs, whereas <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> occurs in the presence of such exposure </plain></SENT>
<SENT sid="1" pm="."><plain>We encountered 4 patients among 217 patients on hydroxychloroquine for rheumatological conditions in 2005 diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Two patients were male and two were female; the median age was 69.75 years, (range 65-76) </plain></SENT>
<SENT sid="3" pm="."><plain>The dose of hydroxychloroquine for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 400 mg daily with median treatment duration of 10.5 years and a range of 6-16 </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had bone marrow biopsy confirmation of the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in a group older than 70 years ranges from 15 to 50/100,000 persons per year </plain></SENT>
<SENT sid="6" pm="."><plain>The diagnosis of 4 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> among 217 patients in 1 year is approximately 123-137-fold higher than the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in the general population aged more than 70 years (P &lt; 0.001) and suggests that long-term treatment with hydroxychloroquine is associated with an increased risk of developing <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> </plain></SENT>
</text></document>